The Quality of Lymph Node Harvests in Extralevator Abdominoperineal Excisions

Ben Liu (Ben.Liu@nhs.net)  
Royal Wolverhampton Hospitals NHS Trust  https://orcid.org/0000-0002-4406-5012

Ja’Quay Farquharson  
Royal Wolverhampton Hospitals NHS Trust

Research article

Keywords: Rectal cancers, abdominoperineal excisions, lymph nodes, histopathology

DOI: https://doi.org/10.21203/rs.3.rs-28901/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:**

Lymph node (LN) harvest in colorectal cancer resections is a well-recognised prognostic factor for disease staging and determining survival, particularly for node-negative (N0) diseases.

Extralevator abdominoperineal excisions (ELAPE) aim to prevent “waisting” that occurs during conventional abdominoperineal resections (APR) for low rectal cancers, and reducing circumferential resection margin (CRM) infiltration rate. Our study investigates whether ELAPE may also improve the quality of LN harvests, addressing gaps in the literature.

**Methods:**

This retrospective observational study reviewed 2 sets of 30 consecutive APRs before and after the adoption of ELAPE in our unit.

The primary outcomes are the total LN count and rates of meeting the standard of 12-minimum, particularly for those with node-negative disease. The secondary outcomes are the CRM involvement rates.

Baseline characteristic including age, sex, laparoscopic or open surgery and neoadjuvant chemoradiotherapy were accounted for in our analyses.

**Results:**

Median LN counts were slightly higher in the ELAPE group (16.5 vs. 15). Specimens failing the minimum 12-LN requirements were almost significantly fewer in the ELAPE group (OR=0.456). Among node-negative rectal cancers, significantly fewer resections failed the 12-LN standard in the ELAPE group than APR group (OR=0.211, p=0.044). ELAPE led to a near-significant decrease in CRM involvement (OR=0.365). These improvements were persistently observed after taking into account baselines and potential confounders in regression analyses.

**Conclusion**

ELAPE provides higher quality of LN harvests that meet the 12-minimal requirements than conventional APR, particularly in node-negative rectal cancers. The superiority is independent of potential confounding factors and may implicate better clinical outcomes.

**Background**

An abdominoperineal Resections (APR) includes the resection of the sigmoid colon, rectum, and anus and the construction of a permanent end colostomy. It is the established curative surgical treatment for low-lying rectal cancers within 4 cm from the anal verge or those involving anal sphincter complexes [1].
However, a high rate of intraoperative bowel perforation (IBP) and risks of positive circumferential resection margin (CRM), both strong predictors of survival [2] had been reported to be as high as 30.4% in the Dutch TME trial [3] and 30.2% in the MERCURY trial [4]. These have subsequently been correlated with higher recurrence rates and reduced survival after APR [5]. Extralevator Abdominoperineal Excision (ELAPE) had been described to standardise a cylindrical specimen without a “waist” in order to minimise the risk of CRM involvement, and early outcomes have been favourable [6–8].

In addition to CRM, the identification of lymph node (LN) metastases following surgical resection for colon and rectal cancer is well recognised as a key prognostic factor[9], and is a pre-requisite in accurate cancer staging [10]. Established evidence had demonstrated strong association between higher total LN counts and improved disease survival [11, 12] particularly for node negative colorectal cancers [12, 13]. This is because in clinical practice, the presence of LN metastasis determines those patients most likely to benefit from adjuvant therapies as shown in multiple key phase III trials such as the MOSAIC trial [14]. Although there are still debates regarding the optimal number of LNs required for adequate staging [15], the evaluation of at least 12 LNs following colorectal resection is widely recommended in most clinical guidelines [16, 17].

Although the rationale and outcomes relating to CRM clearance associated with ELAPE are well documented, there are gaps in the literature regarding the quality of lymph node harvests between the traditional APR technique and ELAPE, and how that may have an impact on recurrences and disease survival. The aim of our observational study is to investigate the number of lymph nodes yielded from ELAPE compared with conventional APR. As evidence had shown diminishing returns from excessive lymph node dissection beyond the recommended 12 lymph nodes [18], our study hence focuses on whether ELAPE may be superior at meeting the 12 LN minimal requirement.

**Methods**

**Study objectives and hypothesis**

The primary objective of this observational study is to determine if ELAPE improves the absolute number of LN yield and the rate of meeting the 12LN minimal requirement, compared with standard APR. The secondary objective is to assess the CRM involvement rates and determining whether the known advantages of ELAPE can be reproduced in a district general hospital setting.

The null hypothesis is finding no differences in the pathological outcomes between the two groups (ELAPE vs. APR) of patients. If there are significant differences, we evaluate whether they are independent of patients’ baseline characteristics and other confounders including the use of open / laparoscopic surgery and neoadjuvant chemoradiotherapy.

**Endpoints**
The primary endpoints are:

Absolute number of lymph node yields
Failure rates to meet the 12 LN nodes pathological requirement
Failure rates to meet the 12 LN pathological requirement in node-negative (N0) subgroups

The secondary endpoint is

The rates of CRM involvement

**Inclusion and exclusion criteria**

Our colorectal unit in The Royal Wolverhampton Hospital NHS Trust adopted ELAPE as a standard procedure for low rectal cancer in 2014. From the register of this single centre, we included patients who underwent the two methods of abdominoperineal resections for rectal cancer (i.e. adenocarcinoma) over a 10 year period between 2009 and 2019.

Patients undergoing revisional or completion procedures or procedures for non-adenocarcinomas were excluded.

**Data Collection**

Two groups of 30 consecutive cases were sampled over three years period before and after our adoption of ELAPE. Case notes were retrospectively reviewed for baseline characteristics including patient age and sex. The operation notes were reviewed to determine the techniques employed and type of access (open or laparoscopic). The uses of any neoadjuvant therapies were documented.

**Statistics**

Data from the United Kingdom National Bowel Cancer Audit [17] showed a median of 15.1 LN harvested from rectal resections and 78.6% of them achieved 12 LN minimum. Shen et al. [19] in 2009 noted the mean number of LN ranges from 13.6 to 19 depending on factors such as age, sex, tumour grade, stage and surgical techniques; the standard deviation was 10.5. Based on this, at the power of 80% the minimum sample size for capturing a 5% difference between the two groups was calculated to be 60.

As the data is not normally distributed, the median number of lymph node yields was recorded. Between the two groups (ELAPE vs. Conventional APR) Mann-Whitney U Test was used to detect any significant differences in the absolute LN yield. Odds ratios were used for differences in the rate of specimens failing the minimum 12-LN requirement, and in analysing differences in the nodal-negative subgroups. The same is applied to differences in the rates of CRM involvement. Regression calculations were performed
to analyse the differences between the two groups independently of potential confounders (baseline characteristics, laparoscopic/open surgery and the use of neoadjuvant therapies).

**Results**

After excluding 7 patients from the APR group and 3 patients from the ELAPE group, there are 30 patients per study group included in the analyses. The exclusions are described in the flow diagram (Fig. 1).

**Baseline Characteristics**

The baseline characteristics are shown in Table 1. There is no statistical difference in the genders of patients between the two groups – 22 male: 8 female in the conventional APR group and 17 male: 13 female in the ELAPE group (p = 0.176). No significant differences (P = 0.930) were observed between the mean age of the APR group (67.8) and the ELAPE group (68.0). Significantly fewer traditional APR cases (4 out of 30) were performed laparoscopically contrary to 11 out 30 in the ELAPE group (P = 0.037). 14/30 patients in the traditional APR group received neoadjuvant chemoradiotherapy, not significantly different (P = 0.606) to the 16/30 in the ELAPE group.

|                          | Conventional APR | ELAPE | P value |
|--------------------------|------------------|-------|---------|
| Male: Female             | 22 : 8           | 17 : 13 | 0.176 |
| Age                      | 67.8             | 68.0  | 0.930  |
| Laparoscopic : Open surgery | 4:26          | 11:19 | 0.037  |
| Neoadjuvant chemoradiotherapy | 14/30      | 16/30 | 0.606  |

**Lymph Node Counts**

The median number of lymph node harvested from conventional APR and ELAPE specimens were 15 and 16.5 respectively (Shown in Table 2) without a significant difference (P = 0.181). The ELAPE group has lower rates of lymph node harvests failing the minimum 12-LN requirement (7/30) compared with the conventional APR group (13/30) with odds ratio of 0.456 which almost reached statistical significance (p = 0.085). In those patients with negative nodal metastases status (N0), the rate of failing the 12-LN requirement is significantly reduced (3/19) in the ELAPE group compared with the APR group (8/17) with odds ratio of 0.211 (P = 0.025). When contrasting the rates of pathological CRM involvement in the specimens, ELAPE (3/30) outperforms conventional APR (7/30) with odds ratio of 0.365, which almost reached statistical significance (p = 0.088).
Regression Analyses

There were no significant independent differences between the two groups in median lymph node counts ($p = 0.224$), rate of failure to reach 12 LN ($p = 0.129$) and the rates of CRM involvement ($p = 0.099$). However in those with nodal negative status (N0), significantly lower failure rates of harvesting 12 LN were persistently observed ($p = 0.044$) in the ELAPE group, suggesting independence from the potential aforementioned confounders.

| Table 2 | Comparisons of pathological results between the ELAPE group and APR group. |
|---------|--------------------------------------------------------------------------------|
|         | Median Total Lymph nodes (LN) | Below 12 LN requirement | Node negative (N0), < 12 LN requirement | CRM involvement | Total number of cases |
| ELAPE   | 16.5                          | 7/30                     | 3/19                                    | 3/30            | 30                   |
| Conventional APE | 15                           | 12/30                    | 8/17                                    | 7/30            | 30                   |
| Statistical tests and significance | Mann-Whitney U Test ( $P = 0.181$) | Odds ratio (OR) = 0.456 ( $P = 0.085$) | OR = 0.211, $P = 0.025$) | OR = 0.365, $P = 0.088$) | 60 |
| Regression analysis (including age, sex, lap/open, neoadjuvants) | $p = 0.224$ | $P = 0.129$ | $P = 0.044$ | $P = 0.099$ | 60 |

Discussion

In this study we have investigated the differences in the number of lymph nodes harvested between ELAPE and conventional APR. The median number of LN yielded from conventional APR is 15. Authors such as Shen et al. 2009 [19] retrospectively inspected 69 cases and had reported the same median number of 15. The absolute LN count in our ELAPE group is higher but not significantly compared to the APR group, and is comparable to the 13.7 nodes from the ELAPE results in the large scale (n = 519) Swedish population study [20]. Neither our study nor the Swedish cohorts found significant differences between APR and ELAPE groups. However, reported number of LN harvest from APEs in literature varies greatly. In general LN counts for abdominoperineal excisions are lower than other type of colorectal resections, and can be as low as 9 LN [21]. Though comparable, the number of lymph nodes harvested at our unit appears higher compared to the reported literature. This may be explained by the contemporaneousness of our data and higher proportion of laparoscopic surgery in our study compared with established evidence. Dolan et al. [22], in a prospective study of 896 patients spanning 20 years
(1997–2016), had found significant independent correlation between later operative date, increasing prevalence of laparoscopic surgery and higher lymph node harvests.

12-LN minimal requirement

Secondly, we have found a reduction in the rate of resections failing to meet the 12-LN minimal requirement under the ELAPE technique compared with traditional APR. The differences are considerable and almost statistically significant. Hitherto; there has been a lack of evidence comparing quality of LN harvests between the two techniques despite emphases of its importance by many authors [13, 23–25] and guidelines including the National Cancer Institute [16]. A minimum of 12 lymph nodes was recommended [23] as below this cut-off value there is a high risk of false-negatives in reporting lymph node metastases due to inadequate sampling [25]. The 12-node standard has been endorsed by other researches for reasons of "diminishing returns" beyond the examination of 12–17 nodes [18]. In our study, 60% and 77% of specimens in the APR and ELAPE groups respectively met this standard. When compared with known literature from authors who specifically investigated the 12-LN criteria among rectal cancers, our cohort of patients have achieved higher rates in general. Field et al. [21] reported 50%, while Gurawalia et al. [26] achieved 52%, and Baxter et al. [27] had a 46.4% attainment rate. Our higher success rate could be explained again by the contemporaneousness of our cases, and a higher prevalence of laparoscopic surgery in our cohort, both considered to be independent determinant of meeting the 12-LN standard as found by Dolan et al. [22]

Node Negative Disease

The British reviewers Ong and Schofield [28] have summarised that node-negative colorectal cancer patients have a 5-year survival rate of 70%-80% in contrast to 30%-60% for their nodal-positive counterparts. Survival can be improved in the latter group by adjuvant chemotherapy [14]. The 20%-30% disease recurrence in apparently completely excised tumours without lymph node metastases is thought to be due to occult lymph node disease [29]. If this subset of patients could be identified by better lymph node staging, they might also benefit from adjuvant chemotherapy. Nodal-positive resections, irrespective of the number of LN harvested, would indicate adjuvant chemotherapy. Therefore substantial researches have investigated how the number of LN examined affects the accuracy of colorectal cancer staging and prognosis among node-negative individuals [12, 30, 31]. As aforementioned, Fielding et al. [23] advocated a minimum of 12 lymph nodes since below this cut-off value there is a high risk of false-negative reporting of lymph node involvement due to inadequate sampling. Based on this evidence, we have conducted a separate analysis of nodal-negative cases investigating whether the minimum 12-LN standard has been met in this subset. We have found significantly lower rates of failures in meeting the 12-LN requirement with ELAPE when compared to APEs. This suggests that ELAPE may be superior at staging rectal cancers, minimising false-negatives in apparently negative nodal disease, leading to more appropriate decision-making on adjuvant treatments. The mechanism underlying the observed
Improvement with ELAPE is not entirely understood, since anatomically the mesorectum tapers as it adjoins the pelvic floor. However as Holms et al. eluded to in their research [6], while other techniques (e.g. intersphincteric, extrasphincteric dissections) are available, ELAPE offers a standardised approach for surgeons to perform abdominoperineal excisions, leading to more consistent quality of resections which in turn reduces the rates of sub-standard TMEs.

CRM Involvement

The overall CRM rate of our cohort is 16.7%, which is relatively high but comparable with published data of 16.6% from Great Britain [32] and 16.7% from Canada [33]. Our study has showed a decreased rate of CRM involvement among the ELAPE group compared with conventional APR, though not quite to a statistically significant level. Most of the studies [20, 34, 35] have also failed to show statistically significant superiority of ELAPE in CRM clearance. However the Danish study [35] suggests a magnitude of reduction (OR 0.386) that is considerable and comparable to our data (OR of 0.365). The more recent, yet small (n = 34) randomised controlled trial, nevertheless, demonstrated a significantly improved CRM and zero intraoperative perforations in their ELAPE arm of patients [36]. Our investigation suggests that the apparent benefit of ELAPE may be reproducible in a district general hospital setting among 8 different local colorectal surgeons who have performed these procedures at our unit.

Potential Confounders

It is established that the quality of surgery and pathologic examination are both major determinants of LN harvests [37, 38]. However, multiple clinicopathologic factors may also affect the number of lymph node retrievals. In particular, a significant reduction in the mean LN yield was found in patients who received neoadjuvant chemoradiotherapy, from 17 to 13 [39], and from an average of 19 to 16 [40]. Other authors such as Field et al. [21] have also found that young, female patients and higher T stages of cancers to be correlated with higher LN yield. There was also significant link between laparoscopic surgery and higher rate of attaining the 12-LN standard [22]. On this basis, we have conducted regression analyses taking into account the above predictors of LN yield as potential confounders. This has not changed the correlations found in our results. The rate of failure to achieving 12 LN standard is significantly lower in the ELAPE group among the nodal negative cohorts. The reduction in CRM involvement is still present but not significant. Our analyses have demonstrated superiority of ELAPE in these pathological aspects independently of other influencing factors.

Limitations

As a retrospective observational study, our investigation is subject to the usual limitations of selection and recall biases. The aim of our research was to establish whether ELAPE leads to a better pathological outcome. Although our results have suggested it, there remains uncertainty whether this would
necessarily translate to an improvement in clinical outcomes i.e. local recurrence rate (LR) and disease survival. Several systematic reviews found no differences in either CRM or LR with ELAPE [34, 41]. Some meta-analyses [42] showed that despite ELAPE significantly lowering the rates of CRM involvement, there has been no benefit in the LR, while others [43], did demonstrate a significant reduction in LR (OR 0.30, P < 0.01). Even if the LR were found to be improved with ELAPE, some authors have found no difference in overall survival, disease free survival or disease progression in a prospective controlled study [44], and from a randomised controlled trial with median follow-up of 20 months [45]. However these studies have been marred by their small recruitment numbers (n = 69 and n = 67 respectively) and short follow-up periods.

It is less disputable, nevertheless, that the retrieval and analysis of a larger number of lymph nodes result in a survival advantage [30]. This was initially thought to be due to upstaging of “missed” positive lymph nodes. However, more recent studies suggest that this phenomenon cannot be attributed to staging migration alone. A systematic review [18] found improved survivals correlating with higher lymph node harvests in stage III (4 of 6 studies) as well as stage II (16 of 17 studies) diseases. Furthermore, lymph node sampling past a certain point does not appear to improve disease staging [46]. Interestingly Joseph et al. [47] Found that improvement in colorectal cancer survival was associated with greater LN harvest irrespective of patients’ nodal statuses (N1 or N0). Tumour-host interactions may be a plausible explanation for this, as higher LN yield may reflect a stronger host immune response [48].

Among other factors that could have influenced our results was the lack of pathological reporting of the lengths of our specimens. This may be because there has not been a standardised length of resection for APEs in general. The amount of mesentery associated with specimen length undoubtedly correlates with the number of LNs found [19].

Secondly, authors such as Dolan et al. [22] have noticed greater number of LN yield to be associated with more contemporaneous operations when comparing cases before and after year 2007. Since our study design is based on the adoption before and after the adoption of ELAPE in year 2014, the latter date of the surgery in the ELAPE group may be a potential bias. Are we simply becoming better surgeons and pathologists as a whole rather than observing improvement due to the merits of the new technique?

Despite our effort to improve LN harvests, no internationally recognised standards of practice have been developed for the histopathological processing of lymph nodes in specimens [49]. A notable Canadian study showed that only 58% of pathologists were aware of current guidelines and that only 25% recognized that a minimum of 12 LNs was necessary for accurate designation of node negativity [50]. On the other hand, the concern with rigidly fixing a recommended number (i.e. 12) is that once this figure is met, the lab search for LNs may end at that point regardless of how many potentially positive nodes are left in the sample [27].

The apparent advantages of ELAPE also need to be balanced with the morbidity this new technique brings. Some authors have reported significantly more post-operative wound infections after ELAPE (20.5%) than for APR (12%) [20]. A prospective multicentred trial [51] also suggested higher rates of
sexual dysfunction, urinary retention, and perineal complications including chronic perineal pain associated with ELAPE. However, a meta-analysis [52] found no differences in complication rates between the two techniques, and some of these potential complications can be mitigated with reconstructions using meshes or plastic surgery. Our enthusiasm for ELAPE should nevertheless be tempered with caution and consideration of its potentially higher complexity and morbidity.

**Abbreviations**

APR
Abdominoperineal Resections

CRM
Circumferential Resection Margin

ELAPE
Extralevator Abdominoperineal Excisions

IBP
Intraoperative Bowel Perforation

LN
Lymph Node

LR
Local Recurrence

**Declarations**

**Ethics approval and consent to participate**

Written informed consents have been obtained from the study subjects. Data were collected, processed and stored in accordance with the Data Protection Act. The study protocol was submitted and approved by Research Ethics Committee via Health Research Authority (UK) IRAS reference ID: 282958

**Consent for publication**

Not applicable
Availability of data and materials

The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

Competing Interests

The authors declare that they have no competing interests.

Funding Sources

No additional source of funding was sought or given.

Author Contributions

Ben Liu: Chief Investigator, case identification, data collection, data analyses, main author

Ja’Quay Farquharson: Sub-investigator, data collection, data analyses, co-author

Acknowledgement

Not applicable

References

1. Perry WB, Connaughton JC. Abdominoperineal resection: How is it done and what are the results? Vol. 20, Clinics in Colon and Rectal Surgery. Thieme Medical Publishers; 2007. p. 213–20.

2. Bernstein TE, Endreseth BH, Romundstad P, Wibe A. Circumferential resection margin as a prognostic factor in rectal cancer. Br J Surg [Internet]. 2009 Nov [cited 2020 Apr 13];96(11):1348–57. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19847867.

3. Nagtegaal ID, Van De Velde CJH, Marijnen CAM, Van Krieken JHJM, Quirke P. Low rectal cancer: A call for a change of approach in abdominoperineal resection. J Clin Oncol [Internet]. 2005 Dec 20 [cited 2020 Apr 13];23(36):9257–64. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16361623.

4. http://ascopubs.doi/10.1200/JCO.2012.45.3258

Taylor FGM, Quirke P, Heald RJ, Moran BJ, Blomqvist L, Swift IR, et al. Preoperative Magnetic Resonance Imaging Assessment of Circumferential Resection MarginPredicts Disease-Free Survival and Local Recurrence: 5-Year Follow-Up Results of the MERCURY Study. J Clin Oncol [Internet]. 2014
5. Hussain A, Mahmood F, Torrance ADW, Clarke H, Howitt C, Dawson R. Oncological outcomes of abdominoperineal resection for the treatment of low rectal cancer: A retrospective review of a single UK tertiary centre experience. Ann Med Surg. 2018 Oct;1:34:28–33.

6. Holm T, Ljung A, Hägemark T, Jurell G, Lagergren J. Extended abdominoperineal resection with gluteus maximus flap reconstruction of the pelvic floor for rectal cancer. Br J Surg [Internet]. 2007 Feb [cited 2020 Apr 14];94(2):232–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17143848.

7. West NP, Finan PJ, Anderin C, Lindholm J, Holm T, Quirke P. Evidence of the oncologic superiority of cylindrical abdominoperineal excision for low rectal cancer. J Clin Oncol [Internet]. 2008 Jul 20 [cited 2020 Apr 14];26(21):3517–22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18541901.

8. De Nardi P, Summo V, Vignali A, Capretti G. Standard Versus Extralevator Abdominoperineal Low Rectal Cancer Excision Outcomes: A Systematic Review and Meta-analysis. Vol. 22, Annals of Surgical Oncology. Springer New York LLC; 2015. p. 2997–3006.

9. Baxter NN, Virmig DJ, Rothenberger DA, Morris AM, Jessurun J, Virmig BA. Lymph node evaluation in colorectal cancer patients: a population-based study. J Natl Cancer Inst [Internet]. 2005 Feb 2 [cited 2020 Apr 14];97(3):219–25. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15687365.

10. Morris EJA, Maughan NJ, Forman D, Morris E, House A. Who to treat with adjuvant therapy in Dukes B/stage II colorectal cancer? The need for high quality pathology. Gut [Internet]. 2007;56:1419–25. [cited 2020 Apr 14]. Available from: www.gutjnl.com.

11. Caplin S, Cerottini JP, Bosman FT, Constanda MT, Givel JC. For patients with Dukes’ B (TNM Stage II) colorectal carcinoma, examination of six or fewer lymph nodes is related to poor prognosis. Cancer [Internet]. 1998 Aug 15 [cited 2020 Apr 15];83(4):666–72. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9708929.

12. Tepper JE, O’Connell MJ, Niedzwiecki D, Hollis D, Compton C, Benson AB, et al. Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol. 2001 Jan 1;19(1):157–63.

13. McDonald JR, Renehan AG, O’Dwyer ST, Haboubi NY. Lymph node harvest in colon and rectal cancer: Current considerations. World J Gastrointest Surg [Internet]. 2012 Jan 27 [cited 2020 Apr 14];4(1):9–19. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22347537.

14. André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol [Internet]. 2009 Jul 1 [cited 2020 Apr 14];27(19):3109–16. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19451431.

15. Wong SL. Lymph node counts and survival rates after resection for colon and rectal cancer. Gastrointest Cancer Res [Internet]. 2009 Mar [cited 2020 Apr 14];3(2 Suppl):S33-5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19461921.
16. Nelson H, Petrelli N, Carlin A, Couture J, Fleshman J, Guillem J, et al. Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst. 2001 Apr 18;93(8):583–96.

17. Smith JJ, Finan PJ. National Bowel Cancer Audit 2009 [Internet]. 2009. Available from: https://files.digital.nhs.uk/publicationimport/pub02xxx/pub02587/nati-clin-audi-supp-prog-bowe-canc-2009-rep2.pdf.

18. Chang GJ, Rodriguez-Bigas MA, Skibber JM, Moyer VA. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst [Internet]. 2007 Mar 21 [cited 2020 Apr 18];99(6):433–41. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17374833.

19. Shen SS, Haupt BX, Ro JY, Zhu J, Bailey HR, Schwartz MR. Number of lymph nodes examined and associated clinicopathologic factors in colorectal carcinoma. Arch Pathol Lab Med. 2009 May;133(5):781–6.

20. Prytz M, Angenete E, Ekelund J, Haglind E. Extralevator abdominoperineal excision (ELAPE) for rectal cancer - Short-term results from the Swedish Colorectal Cancer Registry. Selective use of ELAPE warranted. Int J Colorectal Dis. 2014;29(8):981–7.

21. Field K, Platell C, Rieger N, Skinner I, Wattchow D, Jones I, et al. Lymph node yield following colorectal cancer surgery. ANZ J Surg [Internet]. 2011 Apr [cited 2020 Apr 25];81(4):266–71. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21418471.

22. Dolan RD, McSorley ST, Horgan PG, McMillan DC. Determinants of lymph node count and positivity in patients undergoing surgery for colon cancer. Medicine (Baltimore) [Internet]. 2018 Mar 1 [cited 2020 Apr 18];97(13):e0185. Available from: http://journals.lww.com/00005792-201803300-00025.

23. FIELDING LP, ARSENAULT PA, CHAPUIS PH, DENT O, HARDCASTLE GATHRIGHTB. JD, et al. Clinicopathological staging for colorectal cancer: An International Documentation System (IDS) and an International Comprehensive Anatomical Terminology (ICAT). J Gastroenterol Hepatol. 1991;6(4):325–44.

24. Serrano M, Biondo S. Abdominoperineal excision or extralevator abdominoperineal excision: which is the best oncological treatment? Ann Laparosc Endosc Surg. 2018;3(4).

25. Vather R, Sammour T, Kahokehr A, Connolly A, Hill A. Quantitative lymph node evaluation as an independent marker of long-term prognosis in stage III rectal cancer. ANZ J Surg. 2011 Dec;81(12):883–8.

26. Gurawalia J, Dev K, Nayak SP, Kurpad V, Pandey A. Less than 12 lymph nodes in the surgical specimen after neoadjuvant chemo-radiotherapy: An indicator of tumor regression in locally advanced rectal cancer? J Gastrointest Oncol. 2016;7(6):946–57.

27. Baxter NN, Ricciardi R, Simunovic M, Urbach DR, Virnig BA. An evaluation of the relationship between lymph node number and staging in pT3 colon cancer using population-based data. Dis Colon Rectum [Internet]. 2010 Jan [cited 2020 Apr 18];53(1):65–70. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20010353.

28. Ong MLH, Schofield JB. Assessment of lymph node involvement in colorectal cancer. World J Gastrointest Surg. 2016;8(3):179.
29. Nicastri DG, Doucette JT, Godfrey TE, Hughes SJ. Is occult lymph node disease in colorectal cancer patients clinically significant? A review of the relevant literature. Vol. 9, Journal of Molecular Diagnostics. Association of Molecular Pathology; 2007. p. 563–71.

30. Swanson RS, Compton CC, Stewart AK, Bland KI. The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol Off J Soc Surg Oncol. 2003;10(1):65–71.

31. Le Voyer TE, Sigurdson ER, Hanlon AL, Mayer RJ, Macdonald JS, Catalano PJ, et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: A secondary survey of intergroup trial INT-0089. J Clin Oncol [Internet]. 2003 Aug 1 [cited 2020 Apr 18];21(15):2912–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12885809.

32. Xanthis A, Greenberg D, Jha B, Olafimihan O, Miller R, Fearnhead N, et al. Local recurrence after “standard” abdominoperineal resection: do we really need ELAPE?.

33. Messenger DE, Cohen Z, Kirsch R, O’Connor BI, Victor JC, Huang H, et al. Favorable pathologic and long-term outcomes from the conventional approach to abdominoperineal resection. Dis Colon Rectum. 2011 Jul;54(7):793–802.

34. Ortiz H, Ciga MA, Armendariz P, Kreisler E, Codina-Cazador A, Gomez-Barbadillo J, et al. Multicentre propensity score-matched analysis of conventional versus extended abdominoperineal excision for low rectal cancer. Br J Surg [Internet]. 2014 Jun [cited 2020 Apr 28];101(7):874–82. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24817654.

35. Klein M, Fischer A, Rosenberg J, Gögenur I. ExtraLevatory AbdominoPerineal Excision (ELAPE) Does Not Result in Reduced Rate of Tumor Perforation or Rate of Positive Circumferential Resection Margin: A Nationwide Database Study. Ann Surg [Internet]. 2015 May 1 [cited 2020 Apr 18];261(5):933–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25211268.

36. Bianco F, Romano G, Tsarkov P, Stanojevic G, Shroyer K, Giuratrabocchetta S, et al. Extralevator with vs nonextralevator abdominoperineal excision for rectal cancer: the RELAPe randomized controlled trial. Color Dis [Internet]. 2017 Feb 1 [cited 2020 Apr 18];19(2):148–57. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27369739.

37. Rieger NA, Barnett FS, Moore JWE, Ananda SS, Croxford M, Johns J, et al. Quality of pathology reporting impacts on lymph node yield in colon cancer [6]. J Clin Oncol. 2007;Vol. 25:463.

38. Evans MD, Barton K, Rees A, Stamatakis JD, Karandikar SS. The impact of surgeon and pathologist on lymph node retrieval in colorectal cancer and its impact on survival for patients with Dukes’ stage B disease. Color Dis [Internet]. 2008 Feb [cited 2020 Apr 18];10(2):157–64. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17477849.

39. Rullier A, Laurent C, Capdepon M, Vendrely V, Belleannée G, Bioulac-Sage P, et al. Lymph nodes after preoperative chemoradiotherapy for rectal carcinoma: Number, status, and impact on survival. Am J Surg Pathol [Internet]. 2008 Jan [cited 2020 Apr 16];32(1):45–50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18162769.

40. Morcos B, Baker B, Al Masri M, Haddad H, Hashem S. Lymph node yield in rectal cancer surgery: Effect of preoperative chemoradiotherapy. Eur J Surg Oncol [Internet]. 2010 Apr [cited 2020 Apr
41. Zhou X, Sun T, Xie H, Zhang Y, Zeng H, Fu W. Extralevator abdominoperineal excision for low rectal cancer: A systematic review and meta-analysis of the short-term outcome. Color Dis [Internet]. 2015 Jun 1 [cited 2020 Apr 18];17(6):474–81. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25704132.

42. Negoi I, Hostiuc S, Paun S, Negoi RI, Beuran M. Extralevator vs conventional abdominoperineal resection for rectal cancer—A systematic review and meta-analysis [Internet]. Vol. 212, American Journal of Surgery. Elsevier Inc.; 2016 [cited 2020 Apr 18]. p. 511–26. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27317475.

43. Zhang Y, Wang D, Zhu L, Wang B, Ma X, Shi B, et al. Standard versus extralevator abdominoperineal excision and oncologic outcomes for patients with distal rectal cancer: A meta-analysis. Medicine (Baltimore) [Internet]. 2017 Dec 1 [cited 2020 Apr 12];96(52):e9150. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29384902.

44. Shen Z, Ye Y, Zhang X, Xie Q, Yin M, Yang X, et al. Prospective controlled study of the safety and oncological outcomes of ELAPE procure with definitive anatomic landmarks versus conventional APR for lower rectal cancer. Eur J Surg Oncol. 2015;41(4):472–7.

45. Han JG, Wang ZJ, Wei GH, Gao ZG, Yang Y, Zhao BC. Randomized clinical trial of conventional versus cylindrical abdominoperineal resection for locally advanced lower rectal cancer. Am J Surg [Internet]. 2012 Sep [cited 2020 Apr 18];204(3):274–82. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22920402.

46. Denham LJ, Kerstetter JC, Herrmann PC. The complexity of the count: Considerations regarding lymph node evaluation in colorectal carcinoma [Internet]. Vol. 3, Journal of Gastrointestinal Oncology. Pioneer Bioscience Publishing; 2012 [cited 2020 Apr 18]. p. 342–52. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23205311.

47. J NE, S ER, H AL, W H, R.J. M JSM, et al. Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resection. Ann Surg Oncol [Internet]. 2003 Apr [cited 2020 Apr 28];10(3):213–8. Available from: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed6&NEWS=N&AN=2005162028.

48. Dawson H, Kirsch R, Messenger D, Driman D. A Review of Current Challenges in Colorectal Cancer Reporting. Arch Pathol Lab Med. 2019;143:869–82.

49. Simunovic M, Baxter NN. Lymph node counts in colon cancer surgery: lessons for users of quality indicators. JAMA [Internet]. 2007 Nov 14 [cited 2020 Apr 18];298(18):2194–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18000205.

50. Wright FC, Law CHL, Last LD, Ritacco R, Kumar D, Hsieh E, et al. Barriers to Optimal Assessment of Lymph Nodes in Colorectal Cancer Specimens. Am J Clin Pathol. 2004 May 1;121(5):663–70.

51. Wang Z, Qian Q, Dai Y, Zhang Z, Yang J, Li F, et al. [A prospective multicenter clinical trial of extralevator abdominoperineal excision for locally advanced low rectal cancer]. Zhonghua Wai Ke Za
52. Chen Y, Chi P. [Meta-analysis of extralevator abdominoperineal excision for rectal cancer]. Zhonghua Wei Chang Wai Ke Za Zhi [Internet]. 2017 Mar 25 [cited 2020 Apr 28];20(3):326–32. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28338169.

**Figures**

![Flow chart of case selection for the ELAPE and APR groups](image-url)

**Figure 1**

Flow chart of case selection for the ELAPE and APR groups